Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
this study aims to investigate the effect of low vs high volume- high intensity interval training on functional capacity and quality of life in chronic heart failure patients
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Low volume high intensity interval training | Experimental | This group will receive the usual care (standard medical treatment) in addition to LV-HIIT on a treadmill for 8 weeks, 2 sessions per week. |
|
| high volume high intensity interval training | Experimental | In this group, the patients will receive the usual care (standard treatment) in addition to HV-HIIT on a treadmill for 8 weeks, 2 sessions per week |
|
| control group | Other | It includes 15 patients who will receive standard medical treatment only |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| low-volume high intensity interval training | Other | Low-volume HIIT (LV-HIIT) is a particularly time-efficient subtype of interval training, which has gained increasing attention in recent years. As per the previous definition, these brief training protocols typically involve≤10 min of intense exercise within a session lasting≤30 min including warm-up, recovery phases between intervals, and cool-down |
| Measure | Description | Time Frame |
|---|---|---|
| 6 minute walk test | self-paced submaximal field exercise test to assess submaximal functional capacity of the patient , the distance walked by the patient for six minutes will be measured by meters | at enrolment and at the end of treatment at 8 weeks |
| 2D Echocardiographic parameters | Left ventricle geometry: left ventricular end-diastolic diameter (LVEDD) mm, left ventricular end-systolic diameter (LVESD) mm, left ventricular end-systolic volume (LVESV) ml. and, left ventricular end-diastolic volume (LVEDV) ml. Left ventricle Systolic function: left ventricular ejection fraction (LVEF) % Left ventricle Diastolic function :E wave cm/s: early diastolic mitral inflow velocity, A wave cm/s: diastolic mitral inflow velocity during late atrial contraction , E/A ratio | at enrollment and at the end of treatment at 8 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Minnesota living with heart failure questionnaire (MLHFQ) | The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is the tool most widely used and recognized to assess HRQOL in adults with Hf, was developed in 1987 by Thomas Rector, focusing on the underlying relationship between pathophysiology, symptoms, functional limitations, and psychological distress, it measures the impacts of symptoms and treatment on different dimensions of HRQOL in HF patients. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Based on the Scientific Statement from the American Heart Association: contraindications for exercise Testing and Training. (Fletcher et al., 2013)
Acute decompensated heart failure NYHA class IV
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Aya I Elshenawy | Contact | +01098811085 | dr.aya_ebrahime@yahoo.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Cairo University | Recruiting | Cairo | Giza Governorate | Egypt |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| High volume high intensity interval training | Other | long (2-4 min) bouts of high (not maximum) intensity exercise interspersed with recovery periods which have wide varieties in the protocols according to the intensity, duration, and number of intervals performed |
|
| Standard medical treatment | Drug | standard medical treatment for chronic heart failure as per international guidlines |
|
| at enrollment and at the end of treatment at 8 weeks |